Greenleaf Trust reduced its position in shares of GW Pharmaceuticals PLC- (NASDAQ:GWPH) by 11.9% during the fourth quarter, according to the company in its most recent Form 13F filing with the Securities & Exchange Commission. The firm owned 65,894 shares of the biopharmaceutical company’s stock after selling 8,900 shares during the period. Greenleaf Trust’s holdings in GW Pharmaceuticals PLC- were worth $8,699,000 at the end of the most recent quarter.

A number of other large investors have also recently added to or reduced their stakes in the stock. Wells Fargo & Company MN increased its stake in GW Pharmaceuticals PLC- by 21.8% in the 2nd quarter. Wells Fargo & Company MN now owns 13,962 shares of the biopharmaceutical company’s stock worth $1,399,000 after purchasing an additional 2,500 shares in the last quarter. Ameriprise Financial Inc. increased its stake in GW Pharmaceuticals PLC- by 8.5% in the 2nd quarter. Ameriprise Financial Inc. now owns 2,064 shares of the biopharmaceutical company’s stock worth $207,000 after purchasing an additional 162 shares in the last quarter. Advisor Group Inc. increased its stake in GW Pharmaceuticals PLC- by 10.7% in the 2nd quarter. Advisor Group Inc. now owns 1,500 shares of the biopharmaceutical company’s stock worth $130,000 after purchasing an additional 145 shares in the last quarter. Stifel Financial Corp increased its stake in GW Pharmaceuticals PLC- by 24.4% in the 2nd quarter. Stifel Financial Corp now owns 18,716 shares of the biopharmaceutical company’s stock worth $1,885,000 after purchasing an additional 3,676 shares in the last quarter. Finally, HighTower Advisors LLC increased its stake in GW Pharmaceuticals PLC- by 40.2% in the 2nd quarter. HighTower Advisors LLC now owns 2,865 shares of the biopharmaceutical company’s stock worth $290,000 after purchasing an additional 821 shares in the last quarter. 74.75% of the stock is currently owned by hedge funds and other institutional investors.

GWPH has been the topic of a number of analyst reports. Zacks Investment Research cut GW Pharmaceuticals PLC- from a “hold” rating to a “sell” rating in a research note on Tuesday, December 26th. Cantor Fitzgerald set a $208.00 price objective on GW Pharmaceuticals PLC- and gave the stock a “buy” rating in a research report on Monday, December 4th. Leerink Swann restated a “buy” rating and set a $153.00 price objective on shares of GW Pharmaceuticals PLC- in a research report on Tuesday, January 23rd. Bank of America decreased their price objective on GW Pharmaceuticals PLC- from $160.00 to $158.00 and set a “buy” rating for the company in a research report on Tuesday, November 14th. Finally, Goldman Sachs Group upgraded GW Pharmaceuticals PLC- from a “neutral” rating to a “buy” rating and set a $174.00 price objective for the company in a research report on Thursday, December 14th. Two investment analysts have rated the stock with a sell rating, two have given a hold rating and six have given a buy rating to the company’s stock. GW Pharmaceuticals PLC- presently has a consensus rating of “Hold” and a consensus price target of $146.38.

Shares of GW Pharmaceuticals PLC- (GWPH) opened at $127.32 on Wednesday. GW Pharmaceuticals PLC- has a 1 year low of $92.65 and a 1 year high of $143.37. The company has a market capitalization of $3,536.23, a PE ratio of -15.19 and a beta of 2.50. The company has a debt-to-equity ratio of 0.01, a quick ratio of 11.34 and a current ratio of 11.44.

GW Pharmaceuticals PLC- (NASDAQ:GWPH) last announced its quarterly earnings data on Monday, February 5th. The biopharmaceutical company reported ($2.43) EPS for the quarter, missing the Zacks’ consensus estimate of ($2.03) by ($0.40). GW Pharmaceuticals PLC- had a negative return on equity of 46.94% and a negative net margin of 1,357.98%. The business had revenue of $7.73 million for the quarter, compared to analyst estimates of $2.18 million. equities analysts predict that GW Pharmaceuticals PLC- will post -9.18 earnings per share for the current fiscal year.

TRADEMARK VIOLATION NOTICE: This news story was reported by The Cerbat Gem and is the property of of The Cerbat Gem. If you are accessing this news story on another domain, it was stolen and republished in violation of international copyright and trademark laws. The original version of this news story can be read at https://www.thecerbatgem.com/2018/02/14/gw-pharmaceuticals-plc-gwph-shares-sold-by-greenleaf-trust.html.

GW Pharmaceuticals PLC- Profile

GW Pharmaceuticals plc is a biopharmaceutical company focused on developing and commercializing therapeutics from its cannabinoid product platform in a range of disease areas. The Company’s lead cannabinoid product candidate is Epidiolex, which is a liquid formulation of pure plant-derived cannabidiol (CBD).

Want to see what other hedge funds are holding GWPH? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for GW Pharmaceuticals PLC- (NASDAQ:GWPH).

Institutional Ownership by Quarter for GW Pharmaceuticals PLC- (NASDAQ:GWPH)

Receive News & Ratings for GW Pharmaceuticals PLC- Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for GW Pharmaceuticals PLC- and related companies with MarketBeat.com's FREE daily email newsletter.